Renee M. McGovern

2.1k total citations
50 papers, 1.5k citations indexed

About

Renee M. McGovern is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Renee M. McGovern has authored 50 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 19 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Renee M. McGovern's work include Histone Deacetylase Inhibitors Research (11 papers), Cervical Cancer and HPV Research (8 papers) and Protein Degradation and Inhibitors (7 papers). Renee M. McGovern is often cited by papers focused on Histone Deacetylase Inhibitors Research (11 papers), Cervical Cancer and HPV Research (8 papers) and Protein Degradation and Inhibitors (7 papers). Renee M. McGovern collaborates with scholars based in United States, Switzerland and Netherlands. Renee M. McGovern's co-authors include Bobbie S. Gostout, Joel M. Reid, Matthew M. Ames, David H. Persing, Amy C. Clayton, Hagen Blaszyk, Steve S. Sommer, Eric S. Calhoun, Jeremy C. Smith and Susan M. Blaney and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Renee M. McGovern

49 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Renee M. McGovern United States 22 693 534 316 304 154 50 1.5k
Caj Haglund Finland 26 616 0.9× 800 1.5× 233 0.7× 371 1.2× 181 1.2× 52 1.6k
Qi-Sheng Feng China 25 805 1.2× 711 1.3× 157 0.5× 539 1.8× 115 0.7× 41 1.7k
You-Hong Fan United States 13 817 1.2× 1.0k 1.9× 190 0.6× 185 0.6× 186 1.2× 24 1.6k
Philippe Schafhausen Germany 22 951 1.4× 555 1.0× 130 0.4× 202 0.7× 182 1.2× 70 2.0k
Gerhard Dyckhoff Germany 25 952 1.4× 582 1.1× 252 0.8× 519 1.7× 215 1.4× 66 1.9k
Mark T. Boyd United Kingdom 21 710 1.0× 562 1.1× 81 0.3× 281 0.9× 162 1.1× 36 1.2k
Carter Van Waes United States 18 821 1.2× 647 1.2× 115 0.4× 408 1.3× 147 1.0× 28 1.5k
Norishige Yamada Japan 21 754 1.1× 363 0.7× 124 0.4× 209 0.7× 96 0.6× 30 1.1k
Tibor Görögh Germany 21 444 0.6× 412 0.8× 177 0.6× 235 0.8× 101 0.7× 64 1.2k
Saleh Rachidi United States 16 454 0.7× 544 1.0× 85 0.3× 164 0.5× 105 0.7× 27 1.2k

Countries citing papers authored by Renee M. McGovern

Since Specialization
Citations

This map shows the geographic impact of Renee M. McGovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renee M. McGovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renee M. McGovern more than expected).

Fields of papers citing papers by Renee M. McGovern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renee M. McGovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renee M. McGovern. The network helps show where Renee M. McGovern may publish in the future.

Co-authorship network of co-authors of Renee M. McGovern

This figure shows the co-authorship network connecting the top 25 collaborators of Renee M. McGovern. A scholar is included among the top collaborators of Renee M. McGovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renee M. McGovern. Renee M. McGovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Costello, Brian A., Jun Yin, Renee M. McGovern, et al.. (2020). Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors. Cancer Research. 80(16_Supplement). CT114–CT114. 1 indexed citations
2.
Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883. 26 indexed citations
3.
Goetz, Matthew P., Joel M. Reid, Sumithra J. Mandrekar, et al.. (2013). UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Investigational New Drugs. 31(6). 1559–1567. 16 indexed citations
4.
Schelman, William R., Anne M. Traynor, Kyle D. Holen, et al.. (2013). A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31(6). 1539–1546. 24 indexed citations
5.
Deming, Dustin A., Howard H. Bailey, Jill Kolesar, et al.. (2013). A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational New Drugs. 32(2). 323–329. 39 indexed citations
6.
Muscal, Jodi A., Patrick A. Thompson, Terzah M. Horton, et al.. (2012). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916). Pediatric Blood & Cancer. 60(3). 390–395. 66 indexed citations
7.
Muscal, Jodi A., Philip A. Thompson, Charlotte H. Ahern, et al.. (2011). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology. 29(15_suppl). 9522–9522. 1 indexed citations
8.
Wen, Patrick Y., Vinay K. Puduvalli, John G. Kuhn, et al.. (2011). Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.. Journal of Clinical Oncology. 29(15_suppl). 2032–2032. 4 indexed citations
9.
Pachman, Deirdre R., Debra L. Barton, Amy C. Clayton, et al.. (2011). Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. American Journal of Obstetrics and Gynecology. 206(1). 42.e1–42.e7. 40 indexed citations
10.
Dickson, Mark A., Dana E. Rathkopf, Richard D. Carvajal, et al.. (2010). A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs. 29(5). 1004–1012. 33 indexed citations
11.
Reid, Joel M., Sumithra J. Mandrekar, William S. Harmsen, et al.. (2008). Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations. Cancer Epidemiology Biomarkers & Prevention. 17(3). 674–679. 11 indexed citations
12.
Buhrow, Sarah A., et al.. (2006). LC–MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501). Journal of Chromatography B. 840(1). 56–62. 11 indexed citations
13.
14.
Gostout, Bobbie S., Scott E. Strome, Amy C. Clayton, et al.. (2002). Two Cases of Coincident Carcinomas of the Head and Neck and the Uterine Cervix. Gynecologic Oncology. 85(2). 376–380. 4 indexed citations
15.
Calhoun, Eric S., Renee M. McGovern, Carol A. Janney, et al.. (2002). Host Genetic Polymorphism Analysis in Cervical Cancer. Clinical Chemistry. 48(8). 1218–1224. 65 indexed citations
16.
Strome, Scott E., Anthony E. Brissett, Bobbie S. Gostout, et al.. (2002). Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations.. PubMed. 8(4). 1093–100. 125 indexed citations
17.
Kasperbauer, Jan L., et al.. (2001). Epstein‐Barr Virus DNA Is Not Increased in Tonsillar Carcinoma. The Laryngoscope. 111(5). 811–814. 11 indexed citations
18.
Hartmann, Arndt, Hagen Blaszyk, Renee M. McGovern, et al.. (1996). Overexpression and mutations ofp53 in metastatic malignant melanomas. International Journal of Cancer. 67(3). 313–317. 56 indexed citations
19.
Kovach, J. S., Hagen Blaszyk, Arndt Hartmann, et al.. (1994). Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. The Lancet. 343(8907). 1195–1197. 58 indexed citations
20.
Kovach, John S., Renee M. McGovern, Joslyn Cassady, et al.. (1991). REPORTS. JNCI Journal of the National Cancer Institute. 83(14). 1004–1009. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caj Haglund Breakdown of academic impact, for papers by Qi-Sheng Feng Breakdown of academic impact, for papers by You-Hong Fan Breakdown of academic impact, for papers by Philippe Schafhausen Breakdown of academic impact, for papers by Gerhard Dyckhoff Breakdown of academic impact, for papers by Mark T. Boyd Breakdown of academic impact, for papers by Carter Van Waes Breakdown of academic impact, for papers by Norishige Yamada Breakdown of academic impact, for papers by Tibor Görögh Breakdown of academic impact, for papers by Saleh Rachidi
Rankless by CCL
2026